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Abstract 
 
Introduction: Vildagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4, indicated for 
the treatment of type 2 diabetes mellitus, combined or not with metformin. This study aims to 
evaluate the cost-effectiveness of vildagliptin in the Brazilian context. Areas covered: Using 
MEDLINE, Cochrane Library, Lilacs and CRD, six studies were selected for the economic 
models. This study utilised cost data in the Brazilian health system to provide the context. 
Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a 
challenge for all health care systems. Although guidelines clearly define first-line treatment, 
there are several other promising treatments. Vildagliptin is one of them, resulting in a mean 
lifetime increase of 0.31 years compared to metformin alone and 1.19 more life years 
compared to other metformin combinations. Considering observational data, life years with 
dual vildagliptin-containing treatments were 0.37 more compared to other dual treatments. 
However, its high cost versus generic metformin and its unclear safety profile weakens its 
subsequent cost-effectiveness. Consequently, the incorporation of vildagliptin or its 
combination with metformin is currently not recommended for the Brazilian Health Care 
System. This may change as more data becomes available. 
 
Key words: vildagliptin, cost-effectiveness, Brazil, Type 2 diabetes, metformin 
 
1. Introduction 
 
Diabetes mellitus is a major public health problem. In 2014, it was estimated there were 422 
million people worldwide with the disease, 8.5% of the adult population [1], although others 
estimated 415 million in 2015. In any event, the prevalence is envisaged to increase to 642 
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million by 2040 [2]. Globally, diabetes alone was estimated to kill 4.6 million people in 2013  
[3]. Type 2 diabetes mellitus (T2DM) is the most prevalent of the type, affecting between 
90% and 95% of patients with diabetes. Annual treatment expenditures of people living with 
diabetes is currently estimated at US$827 billion, representing 12% of the total worldwide 
expenditure on health. Approximately half of adults affected by diabetes are currently 
undiagnosed, and it is estimated that one person dies from this disease every six seconds [1,2]. 
 
There are many medicines available for treatment of patients with T2DM. Among these, there 
are insulin preparations including insulin analogues as well as oral and injectable and 
hypoglycemic agents. In the essential medicines lists of Brazil, there are regular and NPH 
insulins, in addition to oral hypoglycemic agents metformin, glibenclamide and gliclazide [4]. 
This alongside encouraging lifestyle changes including diet and exercise. 
 
Antihypertensives, including renin-angiotensin inhibitors, statins and anti-platelet medicines 
are also prescribed concomitantly with hypoglycaemic medicines and insulin to reduce the 
complications of patients with T2DM, which include cardiovascular complications and 
nephropathy [5±7]. Metformin is usually prescribed as first line therapy in patients with 
T2DM given its beneficial effects on HbA1c, weight, and cardiovascular mortality as well as 
its relative safety profile [8±12]. In addition, it has a very low cost compared with newer 
treatments. The place of second line medicines in combination with metformin is now 
becoming clearer following recent studies and meta-analyses. For instance in a recent cohort 
study conducted in the UK, dual treatment with dipeptidyl peptidase-4 inhibitors, also called 
gliptins, and metformin was associated with a decreased risk in heart failure (38%), 
cardiovascular disease (33%) and mortality (48%). Triple treatment with metformin, 
sulphonylureas, and gliptins was also associated with a decreased risk of key outcomes, e.g. 
40% reduction for heart failure, 30% for cardiovascular disease, and 51% for all cause 
mortality [10]. Reductions in cardiovascular events were also seen in other studies [13]. 
However, other authors are more cautious about the impact of dual therapy with gliptins 
reducing cardiovascular risk [14]. Recent reviews have further pointed out that gliptins have a 
neutral effect on cardiovascular outcomes and stroke [15±18]. A crucial area in the 
management of patients with T2DM is adherence to medicines, which is typically seen as sub-
optimal across countries [3,19±21], although studies have suggested greater compliance with 
metformin and the gliptins versus other combinations [22]. 
 
Vildagliptin is a selective dipeptidyl peptidase-4 inhibitor. It acts on the alpha and beta 
pancreatic cells, preventing incretins degradation. With increased levels of these substances, 
there is a good response of the islets of Langerhans to help with glycemic control through 
insulin regulation and glucagon [23]. The potential benefits of vildagliptin include a lower 
incidence of weight gain, hypoglycemia and peripheral oedema compared with other oral 
hypoglycaemic medicines [24]. 
 
The recent beneficial findings with the gliptins including vildagliptin have resulted in the 
Brazilian public health system being sued in the courts and requested to provide vildagliptin 
for patients. This is because of the stated goal of universal access to healthcare for all patients 
in Brazil, with the potential for citizens to take their case to court if they believe they are not 
being treated appropriately [25]. According to data from the federal government in 2014 more 
than 460,000 tablets of vildagliptin were acquired, representing an expenditure of nearly 
US$515,000, with vildagliptin the most requested gliptin in lawsuits. [26]. Brazilian states 
and municipalities also need to fulfil any regional court rulings further increasing sales. This 
is why vildagliptin was chosen for this study as opposed to other gliptins. 
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However, evidence to support the use of vildagliptin in Brazilian context are scarce for both 
monotherapy and combination therapy. To check the relevance or not of the inclusion of 
vildagliptin into Brazilian T2DM guidelines, studies are needed to understand the economic 
impact alongside any clinical benefits. Consequently, we sought to evaluate the cost-
effectiveness of vildagliptin monotherapy or combined with any oral hypoglycemic agent for 
people living with T2DM under Brazilian public health system perspective based on available 
data from clinical trials and observational studies. 
 
2. Methods 
 
2.1. Search strategy 
 
A systematic search using the MEDLINE, Cochrane Library, LILACS (Latin American and 
Caribbean Literature in Health Sciences) and CRD (Center for Reviews and Dissemination) 
databases was conducted in July 2016 to identify published articles assessing the clinical 
outcomes of vildagliptin for diabetes mellitus Type 2. The search strategies were constructed 
with terms related to the disease and the medication. 
 
2.2. Eligibility criteria 
 
Two reviewers were involved in assessing the abstracts and disagreements were resolved by 
consensus. The studies were considered relevant if: (a) they evaluated the treatment of 
patients with type 2 diabetes mellitus; (b) vildagliptin, combined or not with metformin, was 
an arm of the study; (c) comprised a follow-up of at least 52 weeks as this is chronic 
medication with long term outcomes. Following this process, 770 abstracts were identified. 
Six papers were finally selected for the analysis. Data on efficacy, effectiveness and safety of 
treatments were extracted. The complications of the disease were classified according to the 
ICD-10 code, which allows the identification of the associated costs in the databases of the 
Brazilian health system. The definition of outcomes was considered as reported in the studies. 
In particular, hypoglycaemia was defined as symptoms suggestive of low blood glucose 
confirmed by self-monitored blood glucose measurement of < 3.1 mmol/l. 
 
2.3. Economic models 
 
A Markov model was designed considering a hypothetical cohort of T2DM patients, divided 
into groups according to their pharmacotherapy and the type of studies considered. Based on 
the transition probabilities between a stage of the disease and another, this type of model 
DOORZVWKHVLPXODWLRQRIWKHGLVHDVH¶VSURJUHVVLRQLQDSRSXODWLRn according to time cycles. 
Consequently, each stage of the disease is considered in the model as a transition state [27]. 
 
The main objective of treatment is to keep the patient free of T2DM complications. Secondly, 
HbA1c levels are expected to remain below 7.0% to help prevent the complications of T2DM 
including hospitalisation. In this way, the models were developed to assess the efficiency of 
different approaches in keeping patients free of clinical conditions that result in either 
secondary or tertiary care. We did not look further at efficiency based on cost per quality 
adjusted life years (Cost/ QALYs) as no utility data was available in the Brazilian context. 
This is research for the future.  
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To evaluate the retention capacity of patients at the primary care level, all stages of the 
disease that require specialized care were considered absorbent states. Absorbent states are 
those in which the patient does not progress to another state within the built hypothetical 
cohort. 
 
In this study, each cycle has one-year duration and the model comprises a time horizon of 10 
years that starts with the mean age of patients reported in the literature. In the first model 
F\FOHWKHK\SRWKHWLFDOFRKRUW¶VSRSXODWLRQLVFRPSULVHGRILQGLYLGXDOVZLWKT2DM, HbA1c 
higher than 7.0% and no complications from the disease. Transition from the first to the 
second cycle, and successively, takes place according to the probabilities of transition from 
each state. 
 
Models were composed of transition states, mutually exclusive, which correspond to the 
possible stages of the disease. Consequently, transitions were considered from T2DM no 
complications to other states as reported in studies directly comparing vildagliptin with other 
therapeutic alternatives, combined or not with metformin. 
 
Transition probabilities are developed ZLWKGDWDRQGLVHDVH¶VSURJUHVVLRQDQGWKHHIILFDF\RU
effectiveness of the medicines in question. The relevant information was obtained from 
randomized clinical trials and retrospective or prospective observational studies with a 
minimum follow-up of 52 weeks. Studies with short follow-ups were not used because in this 
period there is a greatest reduction in HbA1c and then, its elevation is observed. Studies with 
a minimum follow-up of 52 weeks best represent sustained levels of HbA1c. Consequently, 
study selection was made based on this criterion in our models. 
 
Model 1 was built to evaluate the cost-effectiveness of vildagliptin 50 mg b.i.d. monotherapy, 
compared to metformin 850 mg b.i.d. monotherapy, to avoid the occurrence of hypoglycemic 
events according Schweizer et al (2007) [28]. In Model 2, the cost-effectiveness of 
vildagliptin 50 mg b.i.d. and metformin 850 mg b.i.d. in combination was estimated to avoid 
the occurrence of complications, such as those documented on the clinical trials of Bolli et al 
(2009) [29], Ferrannini et al (2009) [30] and Filozof (2010) [31]. These studies compared this 
combination to, respectively, pioglitazone 30 mg per day, glimepiride 2 to 6 mg per day and 
gliclazide 320 mg per day, all combined with metformin. In Model 3, we considered data 
from observational studies of Mathieu et al (2013) [32] and Montilla et al (2014) [33] to 
estimate the cost-effectiveness of vildagliptin-containing treatments compared to regimens in 
which do not have this medicine. Mathieu et al (2013) reported the comparative effectiveness 
of metformin combined with vildagliptin or to any other oral hypoglycemic agent. In the 
study of Montilla et al (2014), the populations were divided by those that used vildagliptin 
and those that had not used vildagliptin, combined or not with any other oral hypoglycemic 
agent. There was no dose setting in these two studies. 
 
In Model 1, the transition states were the discontinuation of the treatment due to adverse 
events, HbA1c higher than 7.0%, hypoglycemia and death. Model 2 considered the same 
states of Model 1 with the addition of acute coronary syndrome, congestive heart failure, 
stroke, transient ischemic attacks and peripheral arterial disease. In Model 3, as this was 
derived from observational studies, hypoglycemia, renal insufficiency, stroke, pneumonia, 
pericardial effusion, leukemia, colon adenoma, colon cancer, bladder cancer, breast cancer 
and death were considered (Table 1). 
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Table 1. Annual probabilities and costs for the evaluation of vildagliptin-containing treatments for Type 
2 Diabetes Mellitus. 
 
TRANSITION PROBABILITIES 
 
Value Distribution Reference 
Model 1 variables 
Discontinuation of metformin 0.0714 beta[0.0669;0.8701] Schweizer 2007 
Discontinuation of vildagliptin 0.0424 beta[0.0395;0.8930] Schweizer 2007 
Hypoglycemia ± metformin 0.0040 beta[0.0016;0.4032] Schweizer 2007 
Hypoglycemia ± vildagliptin 0.0058 beta[0.0036;0.6139] Schweizer 2007 
HbA1c > 7,0% ± metformin 0.6586 beta[0.6665;0.3454] Schweizer 2007 
HbA1c > 7,0% ± vildagliptin 0.7476 beta[0.7502;0.2533] Schweizer 2007 
Model 2 variables 
TIA ± control 0.0036 beta[0.0014;0.4020] Bolli 2009 
TIA ± vildagliptin 1.00E-06 beta[2.168E±10;0.0002] Bolli 2009 
Stroke ± control 0.0054 beta[0.0045;0.8343] Bolli 2009, Ferrannini 2009 
Stroke ± vildagliptin 0.0006 beta[0.0002;0.3955] Bolli 2009, Ferrannini 2009 
PAD ± control 0.0007 beta[0.0003;0.3961] Ferrannini 2009 
PAD ± vildagliptin 1.00E-01 beta[1.016E±09;0.0010] Ferrannini 2009 
Discontinuation of control 0.0709 beta[0.0705;0.9234] Ferrannini 2009, Filozof 2010 
Discontinuation of vildagliptin 0.0537 beta[0.0531;0.9352] Ferrannini 2009, Filozof 2010 
Hypoglycemia ± control 0.1095 beta[0.1091;0.8877] Bolli 2009, Ferrannini 2009, 
Filozof 2010 
Hypoglycemia ± vildagliptin 0.0137 beta[0.0129;0.9317] Bolli 2009, Ferrannini 2009, 
Filozof 2010 
Heart failure ± control 0.0014 beta[0.0007;0.5108] Ferrannini 2009 
Heart failure ± vildagliptin 0.0014 beta[0.0007;0.5065] Ferrannini 2009 
HbA1c > 7,0% ± control 0.6802 beta[0.6845;0.3219] Filozof 2010 
HbA1c > 7,0% ± vildagliptin 0.7037 beta[0.7078;0.2980] Filozof 2010 
ACS ± control 0.0048 beta[0.0040;0.8262] Bolli 2009, Ferrannini 2009 
ACS ± vildagliptin 0.0036 beta[0.0026;0.7411] Bolli 2009, Ferrannini 2009 
Model 3 variables 
Colon adenoma ± vildagliptin 0.0001 beta[0.0068;92.3680] Montilla 2014 
Stroke ± control 3.2E-05 beta[0.0002;7.6215] Montilla 2014 
Stroke ± vildagliptin 0.0001 beta[0.0068;92.3680] Montilla 2014 
Bladder cancer ± vildagliptin 0.0001 beta[0.0068;92.3680] Montilla 2014 
Colon cancer ± control 0.0001 beta[0.0025;38.9946] Montilla 2014 
Colon cancer ± vildagliptin 0.0001 beta[0.0068;92.3680] Montilla 2014 
Breast cancer ± control 0.0001 beta[0.0025;38.9946] Montilla 2014 
Pericardial effusion ± control 3.2E-05 beta[0.0002;7.6215] Montilla 2014 
Hypoglycemia ± control 0.0117 beta[0.0118;0.9919] Mathieu 2013 
Hypoglycemia ± vildagliptin 0.0025 beta[0.0024;0.9448] Mathieu 2013 
Renal failure ± vildagliptin 0.0001 beta[0.0068;92.3680] Montilla 2014 
Leukemia ± control 0.0001 beta[0.0025;38.9946] Montilla 2014 
Leukemia ± vildagliptin 0.0001 beta[0.0068;92.3680] Montilla 2014 
Pneumonia ± control 0.0001 beta[0.0025;38.9946] Montilla 2014 
COSTS (R$)a 
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Models variables 
Outpatient T2DM 26.2162 gamma[0.2705;0.0103] SIA 
Outpatient hypoglycemia 30.9205 gamma[0.4238;0.0137] SIA 
Inpatient T2DM 486.0846 gamma[0.5056;0.0010] SIH 
Inpatient hypoglycemia 63.8444 gamma[0.9194;0.0144] SIH 
Metformin (tablet) 0.0580 gamma[19.1832;330.4888] BPS 
Salary CHA 185.3712 gamma[38.4035;0.2072] PBH 
Salary HSA 317.7851 gamma[6.2297;0.0196] PBH 
Salary nurse 767.5083 gamma[7.0584;0.0092] PBH 
Salary doctor 2,725.5172 gamma[4.2581;0.0016] PBH 
Salary HST 277.2010 gamma[9.3583;0.0338] PBH 
Salary HSST 617.8480 gamma[4.7421;0.0077] PBH 
Vildagliptin (tablet) 1.9171 gamma[2,215.93;1,155.8974] BPS 
Model 2 variables 
Outpatient TIA 32.6335 gamma[0.7721;0.0237] SIA 
Outpatient stroke 44.1113 gamma[0.5516;0.0125] SIA 
Outpatient PAD 52.9475 gamma[0.4524;0.0085] SIA 
Outpatient heart failure 117.2197 gamma[0.2056;0.0018] SIA 
Outpatient ACS 304.3038 gamma[1.3264;0.0044] SIA 
Inpatient TIA 953.1707 gamma[0.2602;0.0003] SIH 
Inpatient stroke 1,215.7729 gamma[0.2911;0.0002] SIH 
Inpatient PAD 2,526.9404 gamma[0.7360;0.0003] SIH 
Inpatient heart failure 1,552.1003 gamma[0.1607;0.0001] SIH 
Inpatient ACS 3,773.6034 gamma[0.7505;0.0002] SIH 
Control (tablet) 0.4054 gamma[44.497;109.7738] BPS 
Model 3 variables 
Outpatient colon adenoma 132.2865 gamma[5.7146;0.0432] SIA 
Outpatient stroke 44.1113 gamma[0.5516;0.0125] SIA 
Outpatient bladder cancer 318.6474 gamma[0.6069;0.0019] SIA 
Outpatient colon cancer 915.8832 gamma[1.0348;0.0011] SIA 
Outpatient breast cancer 518.3841 gamma[1.8797;0.0036] SIA 
Outpatient pericardial effusion 44.1064 gamma[0.7066;0.0160] SIA 
Outpatient renal failure 62.8281 gamma[0.1348;0.0021] SIA 
Outpatient leukemia 168.0535 gamma[1.2572;0.0075] SIA 
Outpatient pneumonia 26.7389 gamma[0.4439;0.0166] SIA 
Inpatient colon adenoma 3,481.8368 gamma[1.6286;0.0005] SIH 
Inpatient stroke 1,215.7729 gamma[0.2911;0.0002] SIH 
Inpatient bladder cancer 1,227.4688 gamma[0.4330;0.0004] SIH 
Inpatient colon cancer 1,157.0266 gamma[0.6953;0.0006] SIH 
Inpatient breast cancer 781.2555 gamma[0.3663;0.0005] SIH 
Inpatient pericardial effusion 2,745.2068 gamma[0.5862;0.0002] SIH 
Inpatient renal failure 1,835.3242 gamma[0.2704;0.0001] SIH 
Inpatient leukemia 2,494.5476 gamma[0.4101;0.0002] SIH 
Inpatient pneumonia 1,008.7475 gamma[0.2766;0.0003] SIH 
Control (tablet) 1.9082 gamma[37,629.38;1,9719.8255] BPS 
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a Monetary amounts in Brazilian currency. Conversion factor to purchasing power parity: 1.73 (local currency 
per international $), World Bank, 2014. 
ACS: acute coronary syndrome; BPS: Brazilian Health Prices Database; CHA: community health agent; T2DM: 
type 2 diabetes mellitus; HbA1c: glycosylated hemoglobin A1c; HSA: health service agent; HSST: health 
service superior technician; HST: health service technical; PAD: peripheral artery disease; PBH: Municipality of 
Belo Horizonte; PE: pericardial effusion; SIA: Brazilian Outpatient Information System; SIH: Brazilian Hospital 
Information System; TIA: transient ischemic attack. 
 
In models 1 and 2, patients who discontinued treatment due to adverse events, or remained 
with HbA1c higher than 7.0%, followed the hypothetical cohort with rescue therapy 
considering the same transition probabilities for the other stages, except for the increase of, 
respectively, 10% and 30% in the risk of death. Treatment discontinuation due to adverse 
events was considered only in the first two years of the cohort. In Model 3, because there are 
insufficient observational data to model these two clinical conditions, the patients remained in 
the T2DM no complications stage until they went on to some modelled complication. 
 
According to the literature, the average ages of entry for patients in the hypothetical cohorts 
were 53, 58 and 62 years for models 1, 2 and 3, respectively. Since death probabilities in these 
studies were lower compared to the Brazilian population and lower for vildagliptin compared 
to controls, the overall death probability for each age in the Brazilian population was 
considered, in 2014, for the groups treated with vildagliptin. For the comparator groups, the 
same probability has been multiplied by the ratio of its superiority in relation to the value of 
vildagliptin obtained in the study (Table 2). 
 
Table 2. Annual probability of death used in the models for evaluation of vildagliptin-
containing treatments for Type 2 Diabetes Mellitus. 
 
Age 
Model 1a Model 2b Model 3c 
Vildagliptin Metformin Vildagliptin Control Vildagliptin Control 
53 0.0068 0.0140 
    
54 0.0073 0.0150 
    
55 0.0078 0.0161 
    
56 0.0084 0.0173 
    
57 0.0090 0.0186 
    
58 0.0097 0.0199 0.0097 0.0131 
  
59 0.0104 0.0214 0.0104 0.0140 
  
60 0.0111 0.0229 0.0111 0.0150 
  
61 0.0119 0.0246 0.0119 0.0161 
  
62 0.0128 0.0265 0.0128 0.0173 0.0128 0.0155 
63   0.0139 0.0187 0.0139 0.0166 
64   0.0150 0.0203 0.0150 0.0178 
65   0.0163 0.0220 0.0163 0.0191 
66   0.0176 0.0238 0.0176 0.0206 
67   0.0192 0.0259 0.0192 0.0222 
68     0.0209 0.0241 
69     0.0228 0.0261 
70     0.0248 0.0283 
71     0.0270 0.0307 
a Vildagliptin monotherapy vs. metformin monotherapy. 
b Vildagliptin combined with metformin vs. metformin combined with other hypoglycemic agent. 
c Dual vildagliptin-containing treatment vs. other dual treatment. 
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To balance the timeliness and data consistency, all monetary values used are for 2014. 
Medicines prices considered in the study were taken from the Integrated System of 
Administration and General Services (Siasg) through the Health Prices Database (BPS) [26]. 
Through the Hospital Information System (SIH) [34] and the Outpatient Information System 
(SIA) [35], the average costs for hospitalisation and outpatient services for each identified 
transition states were obtained. For these costs, means and standard deviations were 
calculated (Table 1). 
 
Based on the city of Belo Horizonte, Minas Gerais, as a representative city within Brazil, 
average remuneration levels were obtained for health professionals who participate directly in 
the care of patients affected by T2DM in primary care. This includes doctors, nurses, 
community health care workers as well as technicians and other relevant health care workers 
treating these patients technician [36]. Considering a monthly follow, half an hour per month 
was considered the equivalent of the remuneration of each professional for the total annual 
value (Table 1). 
 
Models 1 and 2 considered rescue therapy in cases of discontinuation due to adverse events 
and HbA1c higher than 7.0%. For Model 1, this means adding metformin 850 mg b.i.d. to 
vildagliptin 50 mg b.i.d. and the increase of monotherapy with metformin 850 mg from b.i.d. 
to t.i.d. In Model 2, metformin 850 mg increased from b.i.d. to t.i.d in combination with 
vildagliptin or control (pioglitazone, glimepiride or gliclazide). 
 
In health technology economic evaluations, the use of a discount rate in cost and effectiveness 
analyses is recommended. Where there is often a difference in time between the investment in 
health service resources and benefits in health associated with the investment, we used the 
arbitrary rate of 5% for costs and effects, recommended by the Ministry of Health in Brazil 
when the analysis is for longer than one year [37]. 
 
Effectiveness was measured in life years (LY). A LY was computed for each cycle in which 
patients remained free of complications that resulted in either secondary or tertiary care. We 
also considered, according to each cycle, costs related to their transition states. 
 
At the end of the hypothetical cohort, costs and effectiveness were calculated according to the 
different interventions. For each intervention, the cost-effectiveness ratios (CER) were 
calculated. CER will correspond to the monetary value that will need to be invested in a 
particular treatment in order to obtain a LY under primary care. In this cost-effectiveness 
analysis, currency values were adjusted for purchasing power parity (PPP), whose conversion 
factor was approximately 1.73 (local currency for international $) in 2014 [38]. Adjusted 
values were expressed with currency symbol $. 
 
In this study, the incremental cost-effectiveness ratio (ICER) reflects the cost of a LY gained 
or one hypoglycemia episode avoided compared to other treatments. ICER is the ratio of the 
differences in cost and effectiveness between the assessed therapeutic alternatives. An 
intervention is considered cost-effective in Brazil if the ICER value is lower than the 
Brazilian gross domestic product (GDP) per capita, equivalent to $ 16,210.24 in 2014 [39].  
 
Results obtained by economic evaluations in health are subjected to uncertainties, which are 
mainly justified by the limited data available [37]. In this study, a probabilistic sensitivity 
analysis was conducted to assess how far the uncertainties of variables interfere with an 
outcome. Consequently, a Monte Carlo simulation was performed to generate a sample of 
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1,000 interactions between variables considering willingness to pay between half and one 
GDP per capita. Beta distributions were used for each progression data of the disease and 
gamma distributions for each allocated costs. For presenting random values between 0 and 1, 
beta distribution has its recommended use to simulate distribution of transition probabilities of 
hypothetical cohorts. However, for the cost data, which are not random and cannot be 
negative, the use of gamma distribution for sensitivity analysis is recommended [40]. 
 
3. Results 
 
At the end of ten years, 22.2% of patients who were treated with vildagliptin monotherapy 
and 27.0% of those using only metformin remained without complications and with HbA1c 
levels lower than 7.0%. For treatments in combination, proportions were 23.3% and 15.2% 
for metformin associated with, respectively, vildagliptin and control, i.e. pioglitazone, 
glimepiride or gliclazide. Considering observational data, 81.3% and 71.9% of patients who 
received vildagliptin and control, respectively, remained without complications (Table 3). 
Most of patients showed HbA1c higher than 7.0% at the end of follow-up in models where 
this clinical situation was a transition state. Comparing monotherapies, the proportion of 
patients treated with vildagliptin in this situation was 26.8% higher compared to metformin. 
As for the association between vildagliptin and metformin, the superiority was 56.1% 
compared to control (Table 3).  
 
Table 3. Patients proportion in each transition state at the end of the hypothetical cohort. 
 
Stage 
Model 1a Model 2b Model 3c 
Vildagliptin Metformin Vildagliptin Control Vildagliptin Control 
T2DM without complications 0.2223 0.2696 0.2330 0.1521 0.8126 0.7193 
Discontinuation for adverse events 0.0000 0.0000 0.0000 0.0000 
  
HbA1c > 7,0% 0.6621 0.5223 0.5580 0.3574 
  
Hypoglycemia 0.0137 0.0120 0.0361 0.2590 0.0230 0.1007 
Death 0.1019 0.1960 0.1378 0.1513 0.1605 0.1771 
Acute coronary syndrome 
  
0.0223 0.0242 
  
Heart failure 
  
0.0090 0.0073 
  
Stroke 
  
0.0037 0.0272 0.0007 0.0003 
Transient ischemic attack 
  
0.0000 0.0180 
  
Peripheral artery disease 
  
0.0000 0.0036 
  
Renal failure 
    
0.0007 0.0000 
Colon cancer 
    
0.0007 0.0006 
Colon adenoma 
    
0.0007 0.0000 
Leukemia 
    
0.0007 0.0006 
Bladder cancer 
    
0.0007 0.0000 
Pneumonia 
    
0.0000 0.0006 
Breast cancer 
    
0.0000 0.0006 
Pericardial effusion 
    
0.0000 0.0003 
a Vildagliptin monotherapy vs. metformin monotherapy. 
b Vildagliptin combined with metformin vs. metformin combined with other hypoglycemic agent. 
c Dual vildagliptin-containing treatment vs. other dual treatment. 
 
Among the complications evaluated in the model, acute coronary syndrome showed a higher 
proportion at the end of the model, with 2.2% for patients who were treated with the 
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combination of vildagliptin and metformin and 2.4% for controls. A higher proportion than 
1% was observed only for stroke and transient ischemic attack in patients treated with 
metformin associated with control. In all models, the proportion of death was lower in groups 
treated with vildagliptin, with inferiority ranging between 8.9% and 48.0% (Table 3). 
 
In all models, the total cost of patients' treatment using vildagliptin was greater than those 
who used controls. Values were 27.0%, 22.9% and 12.2% higher considering the models 1, 2 
and 3, respectively. On the other hand, treatments containing vildagliptin offered higher LYs 
with no complications, being, respectively, 4.3%, 19.8% and 5.3% longer than controls. 
Differences between cost and effectiveness of treatment with vildagliptin were higher in all 
comparisons, being 21.7% higher in the comparison of monotherapy with metformin, 2.6% 
higher between combinations and 6.4% above considering observational data (Table 4).  
 
Table 4. Cost-effectiveness of vildagliptin-containing treatments for Type 2 Diabetes Mellitus 
 
Treatment Cost ($) 
Incremental 
cost ($) 
Effectiveness 
(LY) 
Incremental 
effectiveness 
(LY) 
CER ($) ICER ($) 
Model 1a 
Metformin 23,089.40  7.23  3,159.55  
Vildagliptin 29,228.68 6,139.27 7.54 0.31 3,878.25 19,735.91 
Model 2b 
Control 24,123.31  6.01  4,012.62  
Vildagliptin 29,651.22 5,527.91 7.20 1.19 4,119.26 4,659.62 
Model 3c 
Control 26,175.59  6.92  3,783.67  
Vildagliptin 29,373.38 3,197.80 7.29 0.37 4,029.03 8,587.09 
a Vildagliptin monotherapy vs. metformin monotherapy. 
b Vildagliptin combined with metformin vs. metformin combined with other hypoglycemic agent. 
c Dual vildagliptin-containing treatment vs. other dual treatment. 
$: Currency values were adjusted for purchasing power parity (PPP). Conversion factor to purchasing power 
parity: 1.73 (local currency per international $), World Bank, 2014; LY: life years. 
 
ICER of vildagliptin monotherapy compared to metformin was US$19,735.91, which means 
21.7% above the cost-effectiveness threshold set for this study based on the Brazilian context. 
On the other hand, it was below GDP per capita in the other two comparisons. Considering 
the comparison between metformin combined with vildagliptin or other medicines, the ICER 
was equivalent to 28.7% of the considered threshold, totalizing $4,659.62. For the comparison 
involving observational data, the ICER was from $8,587.09, corresponding to 53.0% of GDP 
per capita (Table 4). 
 
According to the sensitivity analysis, considering willingness to pay between half and one 
GDP per capita, none of the simulations for treatment with vildagliptin had a higher 
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proportion of presenting a lower CER compared to controls. The vildagliptin CER was lower 
than the control CER in 0.5% to 12.2% of the simulations in Model 1, 23.4% to 28.9% in 
Model 2 and 3.0% to 5.0% in Model 3 (Figure 1). 
 
Figure 1. Probabilistic sensitivity analysis for the cost-effectiveness of vildagliptin-containing 
treatments for Type 2 Diabetes Mellitus. (a) Vildagliptin monotherapy vs. metformin 
monotherapy; (b) Vildagliptin combined with metformin vs. metformin combined with other 
hypoglycemic agent; (c) Dual vildagliptin-containing treatment vs. other dual treatment. 
 
 
 
In the ICER analysis, these were higher than the willingness to pay in most simulations 
involving treatment with vildagliptin. In addition, in these simulations vildagliptin was more 
expensive and more effective. The simulations proportion in this situation was 86.8%, 65.9% 
and 89.0%, respectively, in the models 1, 2 and 3 (Table 5). 
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Table 5. ICER simulations from the probabilistic sensitivity analysis for the cost-effectiveness 
of vildagliptin-containing treatments for Type 2 Diabetes Mellitus. 
 
Settings 
Proportion (%) 
Model 1a Model 2b Model 3c 
IE>0, IC<0 0.0 0.8 0.0 
IE>0, IC>0, ICER<GDP per capita 12.2 28.1 5.0 
IE<0, IC<0, ICER>GDP per capita 0.0 0.0 0.0 
IE>0, IC>0, ICER>GDP per capita 86.8 65.9 89.0 
IE<0, IC<0, ICER<GDP per capita 0.0 0.0 0.0 
IE<0, IC>0 1.0 5.2 6.0 
IE=0, IC=0 0.0 0.0 0.0 
a Vildagliptin monotherapy vs. metformin monotherapy. 
b Vildagliptin combined with metformin vs. metformin combined with other hypoglycemic agent. 
c Dual vildagliptin-containing treatment vs. other dual treatment. 
IC: incremental cost; IE: incremental effectiveness; GDP: gross domestic product 
 
4. Discussion 
 
Despite treatments with vildagliptin offering longer life without complications, differences 
compared to controls were small in the comparison with metformin or among observational 
data. Difference between treatments combined with metformin was the largest, meaning 
approximately a year and 2 months longer life for patients who received vildagliptin. 
However in all comparisons, treatment's costs with vildagliptin were higher in relation to 
controls especially since metformin is available as a low cost generic in Brazil. 
 
Considering data used and willingness to pay, the use of vildagliptin in T2DM treatment is 
not cost-effective using the definitions in Brazil. This is even more so if a cost/QALY ICER 
was used, which is normally the metric used by health authorities using cost effectiveness 
evaluations in their decision making [8,41±45]. Compared with metformin, the ICER for 
vildagliptin was higher than GDP per capita. Comparing its combination with metformin and 
with other drugs, despite the ICER being lower than GDP per capita, it is predominantly 
higher than the willingness to pay on the uncertainties of variables used. For the same reason, 
treatments involving vildagliptin cannot be considered cost-effective based on available data. 
 
As previously mentioned, oral hypoglycemic agents provided by the Brazilian public health 
system are metformin, glibenclamide and gliclazide. In addition to these, regular and NPH 
insulins are included in the essential drug lists for treatment of people living with Diabetes 
Mellitus. Some Brazilian states have also included insulin analogues in their supply lists [25]. 
Considering the comparison between monotherapies, vildagliptin cannot currently be 
recommended as a substitute of metformin as monotherapy in line with current treatment 
guidelines [10,13,22]. In the assessment of metformin combinations, it is not possible to 
conclude about the superiority of vildagliptin compared to gliclazide, because we needed to 
include data from other medicines in vildagliptin-comparator modelling. The study of Filozof 
et al (2010) was the data source of the combination of gliclazide and metformin, whose 
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variables extracted were HbA1c > 7,0%, hypoglycemia, discontinuation due to adverse events 
and overall death [27]. In fact, the mean values of this study were lower for the combination 
of metformin and gliclazide than vildagliptin combined with metformin, except for 
hypoglycemia. The similarity between the combinations in HbA1c lowering was the 
conclusion of the study. 
 
Comparisons involving observational data were made even though there is acknowledged 
heterogeneity in the patients enrolled. Two studies were used, one of which included any oral 
hypoglycemic agent as a control and the other considered sitagliptin ± a dipeptidyl peptidase-
4 inhibitor currently not provided by Brazilian public health system. Furthermore, most of 
data used in the model was extracted from this study, being the only data source of 
progression to complications. Consequently, in this evaluation, vildagliptin is basically 
compared to other DPP-4 inhibitor. Therefore, its ICER should be interpreted with caution for 
inclusion in the health system drugs list.   
 
Health economic models are a simplification of what is considered as treatment and actual 
clinical prognoses. In this way, treatment of a disease is not typically fully addressed in a 
multifactorial complexity. Economic analysis based on models helps in decision making by 
those responsible for coordinating programs and health services within finite resources. 
Factors, parameters and assumptions considered in the model, as well the non-modeled, 
should be considered for decision making.  
 
We accept a number of limitations with our analysis and review. These include the fact that 
the effectiveness and efficacy data obtained were from non-Brazilian as there was no clinical 
trial or observational data including patients from Brazil populations. We also only included 
studies with longer term follow-up for the reasons discussed in the methodology. In addition, 
available studies typically only had a short follow-up period. In this way, clinical data were 
extrapolated until the end of the hypothetical cohort. Literature on the efficacy and 
effectiveness of vildagliptin is scarce, although approved by the Brazilian regulatory agency 
in 2007. Most studies comprise only 24 weeks of follow-up. Richter et al (2008), in a 
systematic review concerning DPP-4 inhibitors for the treatment of T2DM published by 
Cochrane Collaboration, indicated the urgent need for data about safety and follow up for 
long periods to aid decision making [46].  
 
Shortage of this data is acknowledged in the models presented, implying the potential 
underestimation of disease complications and treatment costs. Waugh et al (2010), in a 
systematic review and economic evaluation of new medications for glycemic control in the 
UK perspective [47], included only one 24-week study, comparing metformin combined with 
vildagliptin or pioglitazone. The results of 52 weeks were published by Bolli et al (2009) and 
included in the models presented in this study [25]. In the economic model, patients¶ starting 
age was 58 years and the follow-up duration was 40 years. Effectiveness ranged from 8.56 
years for men and 9.43 years for women. Considering that life expectancy of Brazilian 
population is lower than in UK, and that the model presented here has a time horizon of 10 
years, it seems reasonable that effectiveness results ranged between 6.01 and 7.54 years. 
 
We are also aware that we only look at ICERs based on LY saved and not cost/QALYs in our 
research. From the perspective of Portuguese health system, Viriato et al (2014) evaluated the 
cost-effectiveness between vildagliptin and metformin compared to metformin with 
sulphonylurea in a period of 40 years of follow-up. For this, they used the UKPDS Outcomes 
Model - model based on data from 30-year United Kingdom Prospective Diabetes Study 
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carried out in English population [48]. Therapeutic alternatives demonstrated similar clinical 
results, with an increase of 2.3% in the quality adjusted life years with the use of vildagliptin 
(5.7681 vs. 5.6401). However, this alternative increased spending by ¼YV
¼13,248), providing DQ,&(5RI¼9,072 [49]. Costs and effectiveness of the different 
therapeutic alternatives were lower than observed in our study. This may be due to the fact 
that Viriato et al did not consider costs with health professionals in their model, but 
considered different clinical complications and having adjusted life years to their quality. 
 
Regarding the Brazilian context, an evaluation was recently performed with saxagliptin 
compared to rosiglitazone and pioglitazone, all combined with metformin, from the 
perspective of private health insurance companies. This study considered the clinical and 
economic data of insurers' records over a three-year time horizon. In all comparisons, the 
authors considered saxagliptin was cost-saving when combined with metformin versus the 
glitazone combinations. However, they did not research saxagliptin as monotherapy [50]. In a 
recent systematic review summarizing the results of the cost-effectiveness assessments of 
gliptins either as monotherapy or in combination, the authors concluded that gliptins 
combined with metformin are a cost-effective option compared to sulfonylureas and insulin. 
However, the quality of these studies was low and there are few studies free of conflicts of 
interest [51]. 
 
In another recent review, the authors considered gliptins cost-effective as add-on to metformin 
compared to sulfonylureas. However, the gliptins were not cost-effective when compared to 
GLP-1 receptor agonists and insulin analog glargine [52]. There were also concerns that the 
analyses were based on studies financed by the manufacturers. In a further cost-effectiveness 
evaluation of combined treatments with metformin, despite no significant differences in 
effectiveness and costs, dapagliflozin was considered cost-effective compared to gliptins from 
the UK Healthcare System Perspective [53]. 
 
In view of the current cost of US$1.11 for a vildagliptin tablet and US$0.03 for a metformin 
tablet in Brazil, only a dramatic reduction in the price of vildagliptin would make this 
treatment become cost-effective in Brazil as monotherapy. Despite recent publications on the 
benefits of dual treatment with gliptins and metformin, doubts still remain about the choice of 
vildagliptin over other gliptins as well as the overall safety of the gliptins [14-18]. The lack of 
safety data precludes the proper assessment of complications associated with this disease or 
other potential events associated with vildagliptin and their costs. Since the first register of 
vildagliptin, there has been concern about their limited effectiveness and the potential 
increased risk of patients experiencing cardiac and liver disorders, infections, pancreatitis, 
anaphylactic reactions, intestinal obstruction, bullous pemphigoid and neoplasms [54]. 
Because of the uncertainties about its safety, the FDA has not currently registered vildagliptin. 
As a result, still a concern in Brazil. 
 
More studies of comparative effectiveness and safety are needed, using real-life data to 
improve our knowledge of vildagliptin especially in Latin American countries such as Brazil. 
Long-term evidence on clinical outcomes, safety and economic implications of new 
antidiabetic drugs are limited in the literature. Such evidence is even more limited on the 
direct comparison between medicines not grouped by pharmacological class [55]. Budgetary 
and logistical impact assessments will also aid decision making. 
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5. Conclusion 
 
Considering the clinical and monetary data from the treatment of T2DM patients, 
monotherapy with vildagliptin is not cost-effective compared to the monotherapy with 
metformin. In combination with metformin, vildagliptin demonstrated a low ICER in relation 
to other controls. However, sensitivity analysis identified a higher probability of this value to 
be more expensive than the willingness to pay threshold in Brazil, as well as in the analysis 
involving observational data comparing vildagliptin combinations in relation to other 
combinations between two oral hypoglycemic agents. Consequently, the incorporation of 
vildagliptin or its combination with metformin is currently not recommended for the Brazilian 
Health Care System. This may change as more long term data becomes available, especially 
safety data given current concerns, and ICER thresholds change. In addition, more studies of 
comparative effectiveness are needed using Brazilian real-life data to further assess the safety, 
effectiveness and cost-effectiveness of vildagliptin especially in combination with metformin. 
This also includes the generation of cost-utility data in the future. These are considerations for 
the future. 
 
6. Expert commentary 
 
The prevalence and expenditure on patients living with type 2 diabetes mellitus (T2DM) is 
increasing challenging healthcare systems especially those striving to provide universal 
healthcare. Typically guidelines for these patients, including Brazil, have metformin and 
sulfonylureas such as glibenclamide and gliclazide first line followed by insulin if needed. 
More recently, vildagliptin as monotherapy, or combined with metformin, has the potential to 
help achieve glycemic control as well as decrease episodes of hypoglycaemia and peripheral 
edema. However, there are concerns with its cost-effectiveness in Brazil where new 
treatments are considered as cost-effective at between half and one GDP per capita. 
Developed models showed that the use of vildagliptin increased life by a mean of 0.31 years 
compared to metformin and 1.19 more life years when combined with metformin when 
compared to other metformin combinations. However, despite reducing the occurrence of 
hypoglycemic events and increasing life expectancy, treatments for patients with T2DM 
containing vildagliptin are not currently considered cost-effective from the perspective of the 
Brazilian Health System. 
 
7. Five-year perspective 
 
It is likely that metformin and sulfonylureas will remain first choice treatments for patients 
with T2DM in Brazil over the next 5 years given the published evidence and their continued 
low costs. For patients where these medications are no longer sufficient for glycemic control, 
insulin administration or additional oral treatments with the gliptins such as vildagliptin will 
increasingly be used. New studies will provide insights into the safety, the risk of 
anaphylactic reactions as well as the potential for increased infections, pancreatitis and 
bullous pemphigoid with vildagliptin. However, unless new evidence points to an improved 
safety profile and effectiveness, it is unlikely that vildagliptin will be included within the 
Public Health System in Brazil unless the economic thresholds appreciably change.  
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8. Key issues: 
 
x The prevalence and costs associated with Type 2 diabetes is increasing. New treatents are 
welcomed; however they need to be cost-effective to be affordable within public 
healthcare systems 
x Considering the willingness to pay up to a per capita GDP, vildagliptin monotherapy is 
not currently considered cost-effective compared to metformin monotherapy within the 
Brazilian public healthcare system 
x Despite the low ICER of vildagliptin combined with metformin compared to other 
metformin combinations, we identified a higher probability of this value to be above the 
willingness to pay threshold based on Markov models and simulations 
x Involving observational data, despite the low ICER, vildagliptin-containing treatments 
have again a lower probability to be below the cost-effectiveness threshold. 
x Incorporation of vildagliptin or its combination with metformin is not currently 
recommended for the Brazilian Health System. This may change, especially for 
vildagliptin combined with metformin, once more long-term safety and outcome are 
reported. 
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